Fund an oncology joint assessment unit inside the African Medicines Agency
Africa's new continental medicines agency could assess cancer drugs once for 55 countries. It needs oncology reviewers and a reliance rule to do it.
The African Medicines Agency is becoming operational, building on AVAREF and regional harmonisation initiatives (EAC, SADC). Oncology medicines are a small share of African registrations and most national agencies lack oncology reviewers. The proposal is a philanthropically funded oncology unit within AMA running continental joint assessments, relying on WHO-listed authority reports, with member states committing to national decisions within 60 days of an AMA recommendation. The WHO/St Jude childhood cancer medicines platform provides demand.
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
Pages like this
not linked directly; found by shared links- Idea90-day reliance approval for cancer drugs cleared by two stringent regulators
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
- IdeaLive tracker of the lag from first approval to real availability in every country
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
- InstitutionComisión Federal para la Protección contra Riesgos Sanitarios
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
- IdeaReciprocal recognition of tumour-agnostic and rare-indication approvals across regulators
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
- ProductTrastuzumab biosimilars
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
- IdeaGet the one approved appetite drug licensed beyond a single country
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.
- TermBiosimilar
Shares Regulatory divergence between regions, Most of the world has almost no cancer care.